Farmaceutické aspekty živočíšnej lipoxygenázy

1. Shibata, D., Axelrod, B.: Plant lipoxygenases. J. Lipid Mediat. Cell Signal. 1995; 12, 213–228.

2. Brash, A. R.: Lipoxygenases: occurence, functions, catalysis, and acquisition of of substrate. J. Biol. Chem. 1999; 274, 23479–23682.

3. Andreou, A., Feussner, I.: Lipoxygenases – structure and reaction mechanism. Phytochemistry 2009; 70, 1504–1510.

4. Veldink, G. A., Hilbers, M. P., Nieuwenhuizen, W. F.: Plant lipoxygenase: structure and mechanism. In: Rowley, A.F., Kühn, H., Schewe, T. eds. Eicosanoid and related compounds in plants and animals, London, Portland Press, 1998.

5. Ueda, N., Suzuki, H., Yamamoto, S.: Mammalian lipoxygenases. Structure, functions and evolutionary aspects. In: Rowley, A. F., Kühn, H., Schewe, T. eds. Eicosanoid and related compounds in plants and animals. London: Portland Press, 1998, 47–48.

6. Bisakowski, B., Perraud, X., Kermasha, S.: Characterization of hydroperoxides and carbonyl compounds obtained by lipoxygenase extracts of selected microorganisms. Biosci. Biotechnol. Biochem. 1997; 61, 1262–1269.

7. Brash, A. R., Boeglin, W. E., Chang, M. S., Shieh, B. H.: Purification and molecular cloning of an 8R-lipoxygenase from the coral Plexaura homomalla reveal the related primary structures of R- and S-lipoxygenases. J. Biol. Chem. 1996; 271, 20949–20957.

8. Porta, H., Rocha-Sosa, M.: Lipoxygenase in bacteria: a horizontal transfer event? Microbiology 2001; 147, 3199–3200.

9. Tapiero, H., Ba, G. N., Couvreur, P., Tew, K. D.: Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed. Pharmacother. 2002; 56, 215–222.

10. van Leyen, K., Duvoisin, R. M., Engelhardt, H., Wiedmann, M.: A function for lipoxygenase in programmed organelle degradation. Nature 1998; 395, 392–395.

11. Hill, E. M., Eling, T. E., Nettesheim, P.: Changes in expression of 15-lipoxygenases and prostaglandin H-synthase during differentiation of human tracheobronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 1998; 18, 662–669.

12. Chavis, C., Vachier, I., Bousquet, J., Godard, P., Chanez, P.: Generation of eicosanoid from 15(S)-hydroxyeicosatetraenoic acid in blood monocytes from steroid-dependent asthmatic patients. Biochem. Pharmacol. 1998; 56, 535–541.

13. Salari, H., Chan-Yeung, M.: Release of 15- hydroxyeicosatetraenoic acid (15-HETE) and prostaglandin E2 (PGE2) by cultured human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 1989; 1, 245–250.

14. Hill, E. M., Eling, T. E., Nettesheim, P.: Differentiation dependency of eicosanoid enzyme expression in human tracheobronchial cells. Toxicol. Lett. 1998; 96, 239–244.

15. Conrad, D. J., Lu, M.: Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am. J. Respir. Cell Mol. Biol. 2000; 22, 226–234.

16. Moore, P. E., Lahiri, P., Laporte, J. D., Church, T., Panettieri Jr., R. A., Shore, S. A.: Selected contribution: synergism between TNF-alpha and IL-1b in airway smooth muscle cells: implications for b-adrenergic responsiveness. J. Appl. Physiol. 2001; 91, 1467–1474.

17. Campbell, A. M., Chanez, P., Vignola, A. M., Bousquet, J.: Functional characteristics of bronchial epithelium obtained by brushing from asthmatic and normal subjects. Am. Rev. Respir. Dis. 1993; 147, 529–534.

18. Levy, B. D., Romano, M., Chapman, M. A., Reilly, J. J.: Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 1993; 92, 523–531.

19. Kasahara, Y., Tuder, R. M., Cool, C. D., Voelkel, N. F.: Expression of 15-lipoxygenase and evidence for apoptosis in the lungs from patients with COPD. Chest 2000; 117, 260.

20. Zhu, J., Kilty, I., Granger, H., Gamble, E., Qiu, Y.S., Hattotuwa, K., Elston, W., Liu, W.L., Oliva, A., Pauwels, R.A., Kips, J.C., De Rose, V., Barnes, N., Yeadon, M., Jenkinson, S., Jeffery, P.K.: Gene expression and immunolocalisation of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis. Am. J. Respir. Cell Mol. Biol. 2002; 27, 666–667.

21. Baer, A. N., Costello, P. B., Green, F. A.: Stereospecifity of the products of the fatty acids oxygenases derived from psoriatic scales. J. Lipid Res. 1991; 32, 341–347.

22. Boeglin, W. E., Kim, R. B., Brash, A. R.: A 12R-lipoxygenase in human skin: Mechanistic evidence, molecular cloning, and expression. Biochemistry 1998; 95, 6744–6749.

23. Jobard, F., Lefevre, C., Karaduman, A., Blanchet-Bardon, C., Emre, S., Weissenbach, J., Ozgüc, M., Lathrop, M., PrudęHomme, J. F., Fischer, J.: Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum. Mol. Genet. 2002; 11, 107–113.

24. Donoiwitz, M.: Arachidonic acid metabolites and their role in inflammatory bowel disease. Gastroenterology 1985; 88, 580–587.

25. Zijlstra, F. J., van Dijk, A. P., Garrelds, I. M., Ouwendijk, R. J. T., Wilson, J. H. P.: Species differences in the pattern of eicosanoids produced by inflamed and non-inflamed tissue. Inflamm. Res. 1991; 36, 73–75.

26. Liagre, B., Vergne, P., Rigaud, M., Beneytout, J. L.: Arachidonate 15-lipoxygenase of reticulocyte-type in human rheumatoid arthritis type B synoviocytes and modulation of its activity by proinflammatory cytokines. J. Rheumatol. 1999; 26, 1044–1051.

27. Jankum, J., Aleem, A.M., Malgorzewicz, S., Szkunlarek, M.: Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12‑lipoxygenase and reduce sprout formation of human endothelial cells. Mol. Cancer Ther. 2006; 5, 1371–1382.

28. Honn, K. V., Tang, D. G., Gao, X., Butovich, I. A., Liu, B., Timar, J., Hagmann, W.: 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 1994; 13, 365–369.

29. Nie, D., Che, M., Grignon, D., Tang, K., Honn, K. V.: Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 2001; 20, 195–206.

30. Ikawa, H., Kamitani, H., Calvo, B. F., Foley, J. F., Eling, T. E.: Expression of 15-lipoxygenase in human colorectal cancer. Cancer Res. 1999; 59, 360–366.

31. Kamitani, H., Geller, M., Eling, T. E.: Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J. Biol. Chem. 1998; 273, 21569–21577.

32. Kamitani, H., Eling, T. E., Kameda, H., Kelavkar, U. K.: A GATA binding site is involved in the regulation of 15-lipoxygenase expression in human colorectal carcinoma cell line, caco-2. FEBS Lett. 2000; 467, 341–347.

33. Li, N., Sood, S., Wang, S., Fang, M.: Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin. Cancer Res. 2005; 11, 2089–2096.

34. RĆdmark, O.: 5-lipoxygenase-derived leukotrienes, mediators also of atherosclerotic inflammation. Arterioscler. Thromb. Vasc. Biol. 2003; 23, 1140–1142.

35. Melissa, E., Hatley, S.S., Kelly, B., Reilly, D.T., Hedrick, C.C.: Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J. Biol. Chem. 2003; 28, 25369–25375.

36. Mehrabian, M., Allayee, H., Wong, J., Shi, W., Wang, X. P., Shaposhnik, Z., Funk, C. D., Lusis, A. J.: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis. Circ. Res. 2002; 91, 120–126.

37. Spanbroek, R., Gräbner, R., Lötzer, K., Hildner, M., Urbach, A., Rühling, K., Moos, M. P. W., Kaiser, B., Cohnert, T. U., Wahlers, T., Zieske, A., Plenz, G., Robenek, H., Salbach, P., Kühn, H., RĆdmark, O., Samuelsson, B., Habenicht, A. J. R.: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 2002; 100, 1238–1243.

38. Patricia, M. K., Kim, J. A., Harper, C. M., Shih, P. T.: Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1999; 19, 2615–2622.

39. Eizirik, D. L., Mandrup-Poulsen, T.: A choice of death – the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44, 2115–2133.

40. Bleich, D., Chen, S., Gu, J. L., Thomas, L., Scott, S., Gonzales, N., Natarajan, R., Nadler, J. L.: Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells. Endocrinology 1995; 136, 5736–5744.

41. Ma, Z., Ramanadham, S., Corbett, J. A., Bohrer, A., Gross, R. W., McDaniel, M. L., Turk, J.: Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. J. Biol. Chem. 1996, 271, 1029–1042.

42. Bleich, D., Chen, S. Y., Zipser, B., Sun, D. X., Funk, C. D., Nadler, J.: Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J. Clin. Invest. 1999; 103, 1431–1436.

43. Antonipillai, I., Nadler, J., Vu, E. J., Bughi, S., Natarajan, R., Horton, R.: A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J. Clin. Endocrinol. Metab. 1996; 81, 1940–1945.

44. Pace-Asciak, C. R., Demin, P. M., Estrada, M., Liu, G.: Hepoxilins raise circulating insulin levels in vivo. FEBS Lett. 1999; 461, 165–168.

45. Falck, J. R., Manna, S., Moltz, J., Chacos, N., Capdevila, J.: Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem. Biophys. Res. Commun. 1983; 114, 743–749.

46. Noiri, E., Yokomizo, T., Nakao, A., Izumi, T., Fujita, T., Kimura, S., Shimizu, T.: An in vivo approach showing the chemotactic activity of leukotriene B4 in acute renal ischemic-reperfusion injury. Proc. Natl. Acad. Sci. USA 2000; 97, 823–828.

47. Rabb, H., OęMeara, Y. M., Maderna, P., Coleman, P., Brady, H. R.: Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int. 1997; 51, 1463–1468.

48. Rifai, A., Sakai, H., Yagame, M.: Expression of 5‑lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis. Kidney Int. 1993; 43, 95–99.

49. Henderson, W. R.: Products of 12- and 15-lipoxygenase. In: Henson, P.M., Murphy, R.C. eds. Mediators of the inflammatory process, Handbook of inflammation, Elsevier, Amsterdam, 1989.

50. Liaw, Y. W., Liu, Y. W., Chen, B. K., Chang, W. Ch.: Introduction of 12-LOX exspression by phorbol 12-myristate 13-acetate in human epidermoid carcinoma A431 cell. Bioch. Biophys. Acta 1998; 1389, 23–33.

51. Bors, W., Heller, W., Michel, C., Saran, M.: Flavonoids as antioxidants: Determination of radical-scavenging efficiencies. Metods Enzymol. 1990; 186, 343–345.

52. van Acker, S. A., Koymans, L. M., Bast, A.: Molecular pharmacology of vitamin E: Structural aspects of antioxidant activity. Free Radic. Biol. Med. 1993; 15, 311–328.

53. Sun, A. Y., Simonyi, A., Sun, G. Y.: The „French paradox“ and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 2002; 32, 314–318.

54. Renaud, S., de Lorgeril, M.: Wine, alcohol, platelets and the french paradox for coronary heart disease. Lancet 1992; 339, 1523–1526.

55. Soleas, G. J., Diamandis, E. P., Goldberg, D. M.: Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 1997; 11, 287–313.

56. Bertolini, A., Leone, S., Ottani, A.: Dual acting anti-inflammatory drugs. Curr. Top. Med. Chem. 2007; 7, 265–275.

57. Young, R. N.: Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur. J. Med. Chem. 1999; 34, 671–685.

58. Schewe, T.: Molecular actions of ebselen – an antiinflammatory antioxidant. Gen. Pharmacol. 1995; 26, 1153–1169.

59. Gao, J. X., Issekutz, A. C.: The effect of ebselen on polymorphonuclear leukocyte and lymphocyte migration to inflammatory reactions in rats. J. Immunopharmacol. 1993; 25, 239–251.

60. Takasago, T., Peters, E. E., Graham, D. I., Masayasu, H., Macrae, I. M.: Neuroprotective efficacy of ebselen, an antioxidant with anti-inflammatory actions, in rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. 1997; 122, 1251–1256.

61. Schewe, C., Schewe, T., Wendel, A.: Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione. Biochem. Pharmacol. 1994; 48, 65–74.

62. Fischer, S. M., Klein, R. D.: Lipoxygenases as targets for cancer prevention. In: Kelloff, G. J., Hawk, E. T., Sigman, C. C. eds. Cancer chemoprevention: Promising cancer chemopreventive agents, Humana Press, New Jersey, 2004.

63. Chauret, N., Li, C., Ducharme, Y., Trimble, L. A., Yergey, J. A., Ramachandran, C., Nicoll-Griffith, D. A.: In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L‑702,539. Drug Metabol. Dispos. 1995; 23, 65–71.

64. Funk, C. D.: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294, 1871–1875.

65. Cao, Y., Prescott, S. M.: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell Physiol. 2002; 190, 279–286.

66. Datta, K., Biswal, S. S., Kehrer, J. P.: The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem. J. 1999; 340, 371–375.

67. Avis, I., Hong, S. H., Martinez, A., Moody, T., Choi, Y. H., Trepel, J., Das, R., Jett, M., Mulshine, J. L.: Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. Faseb J. 2001; 15, 2007–2009.

68. Tang, D. G., La, E., Kern, J., Kehrer, J. P.: Fatty acid oxidation and signaling in apoptosis. Biol. Chem. 2002; 383, 425–442.

69. Datta, K., Biswal, S. S., Xu, J., Towndrow, K. M., Feng, X., Kehrer, J. P.: The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. J. Biol. Chem. 1998; 273, 28163–28169.

70. Tong, Z., Wu, X., Kehrer, J. P.: Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem. J. 2003; 372, 203–210.

71. Hamilton, A. L., Watson, R. M., Wyile, G., OęByrne, P. M.: Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997; 52, 348–354.

72. Gambaro, G.: Strategies to safely interfere with prostanoid activity while avoiding adverse renal effects: could COX-2 and COX-LOX dual inhibition be the answer? Nephrol. Dial. Transplant. 2002; 19, 1159–1116.

73. Sala, A., Zarini, S., Bolla, M.: Leukotrienes: lipid bioeffectors of inflammatory reactions. Biochemistry (Mosc.) 1998; 63, 84–92.

74. Martel-Pelletier, J., Lajeunesse, D., Reboul, P., Pelletier, J. P.: Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective nonsteroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003; 62, 501–509.

75. Serhan, C. N., Levy, B. D., Clish, C. B., Gronert, K., Chiang, N.: Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in antiinflammation: a window for therapeutic opportunity. Ernst Schering Res. Found. Workshop 2000; 31, 143–185.

76. Leone, S., Ottani, A., Bertolini, A.: Dual acting anti-inflammatory drugs. Curr. Top. Med. Chem. 2007; 7, 265–275.

77. Laufer, S.: Discovery and development of ML3000. Inflammopharmacology 2001; 9, 101–112.

78. Fiebich, B. L., Hofer, T. J., Lieb, K., Huell, M., Butcher, R. D., Schumann, G., Schulze-Osthoff, K., Bauer, J.: The non-steroidal antiinflamatory drug tepoxalin inhibits interleukin-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkB-alpha. Neuropharmacol. 1999; 38, 1325–1333.

79. Kramer, B. C., Yabut, J. A., Cheong, J., Jnobaptiste, R., Robakis, T., Olanow, C. W., Mytilineou, C.: Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur. J. Neurosci. 2004; 19, 280–286.

80. de Gatetano, G., Donati, M. B., Cerletti, C.: Prevention of thrombosis and vascular inflamation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol. Sci. 2003; 24, 245–252.